<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078230</url>
  </required_header>
  <id_info>
    <org_study_id>IHCC-china</org_study_id>
    <nct_id>NCT04078230</nct_id>
  </id_info>
  <brief_title>Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node
      metastasis is an important factor affecting the poor prognosis of intrahepatic
      cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph
      nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also
      recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic
      cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes
      have similar survival rates. This contradictory result has prompted more scholars to conduct
      clinical research to explore the necessity and standardization of lymph node dissection in
      intrahepatic cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Expanding lymph node dissection can theoretically obtain more lymph node dissection.
      Obtaining enough lymph nodes can improve the accuracy of AJCC staging and accurately
      determine prognosis. However, it is unclear whether it will improve the prognosis of patients
      with lymph node dissection. According to literature reports and related studies, expanded
      lymph node dissection for right liver tumors included stations 12, 8, and 13, and left
      lymphoma expanded lymph node dissection includedstations 12, 1, 3, 7, and 8.

      In summary, standardize the extent of lymph node dissection in intrahepatic
      cholangiocarcinoma, and obtain enough lymph node dissection under the premise of controlling
      the complication rate, which is helpful for accurate TNM staging, accurate judgment of
      prognosis and improvement of survival time. Improve prognosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>resectable intrahepatic cholangiocarcinoma</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>5 years after surgery</time_frame>
    <description>disease free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year Overall survival (OS)</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>3-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Postoperative Complications (PC)</measure>
    <time_frame>From the date of surgery to stitches off (up to 2 month)</time_frame>
    <description>Postoperative Complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year Overall survival (OS)</measure>
    <time_frame>5 years after surgery</time_frame>
    <description>5-year Overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Extend LymphAdenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional LymphAdenectomy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Regional lymph node dissection for intrahepatic cholangiocarcinoma included station 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extend LymphAdenectomy</intervention_name>
    <description>Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors</description>
    <arm_group_label>Extend LymphAdenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years of age and â‰¤80 years of age;

          -  Preoperative imaging and laboratory examination for intrahepatic cholangiocarcinoma,
             intraoperative frozen and postoperative pathology confirmed as intrahepatic
             cholangiocarcinoma; preoperative imaging assessment is resectable;

          -  No obvious lymph node metastasis in preoperative imaging; or negative intraoperative
             lymph node biopsy

          -  Liver function Child-Turcotte-Pugh score A-B grade;

          -  Residual liver volume &gt;30%; can tolerate radical hepatectomy

          -  The patient has autonomy, understands and voluntarily signs the written informed
             consent and is able to complete the follow-up plan;

          -  Sign the written informed consent form prior to the test screening.

        Exclusion Criteria:

          -  The patient has obvious heart, lung, brain and kidney dysfunction that affects the
             treatment of intrahepatic cholangiocarcinoma;

          -  The patient has a history of other malignant tumors;

          -  Liver function Child-Turcotte-Pugh score C;

          -  The investigator determined that it was not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiang-Tao LI, PHD;MD</last_name>
    <phone>86-13666651245</phone>
    <email>zjulijiangtao@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin He, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiying Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiming Zhao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianhai Mao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengxia Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Gong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhong Shan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houbao Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi 'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Geng, MD</last_name>
      <email>gengzhimin@mail.xjtu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuyu Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang-tao Li, MD</last_name>
      <phone>86-13666651245</phone>
      <email>zjulijiangtao@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang cancer hospital</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinbao Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Njei B. Changing pattern of epidemiology in intrahepatic cholangiocarcinoma. Hepatology. 2014 Sep;60(3):1107-8. doi: 10.1002/hep.26958. Epub 2014 Jul 28.</citation>
    <PMID>24327308</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang XF, Chakedis J, Bagante F, Chen Q, Beal EW, Lv Y, Weiss M, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. Br J Surg. 2018 Jun;105(7):857-866. doi: 10.1002/bjs.10827. Epub 2018 Apr 14.</citation>
    <PMID>29656380</PMID>
  </results_reference>
  <results_reference>
    <citation>Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015 Aug;17(8):669-80. doi: 10.1111/hpb.12441.</citation>
    <PMID>26172134</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim DH, Choi DW, Choi SH, Heo JS, Kow AW. Is there a role for systematic hepatic pedicle lymphadenectomy in intrahepatic cholangiocarcinoma? A review of 17 years of experience in a tertiary institution. Surgery. 2015 Apr;157(4):666-75. doi: 10.1016/j.surg.2014.11.006. Epub 2015 Feb 12.</citation>
    <PMID>25682172</PMID>
  </results_reference>
  <results_reference>
    <citation>Shimada M, Yamashita Y, Aishima S, Shirabe K, Takenaka K, Sugimachi K. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg. 2001 Nov;88(11):1463-6.</citation>
    <PMID>11683741</PMID>
  </results_reference>
  <results_reference>
    <citation>Lendoire JC, Gil L, Imventarza O. Intrahepatic cholangiocarcinoma surgery: the impact of lymphadenectomy. Chin Clin Oncol. 2018 Oct;7(5):53. doi: 10.21037/cco.2018.07.02. Epub 2018 Jul 17. Review.</citation>
    <PMID>30180752</PMID>
  </results_reference>
  <results_reference>
    <citation>Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, Aldrighetti L, Calise F, Gerunda GE, Tomatis M, Amisano M, Berloco P, Torzilli G, Capussotti L; Italian Intrahepatic Cholangiocarcinoma Study Group. Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. Arch Surg. 2012 Dec;147(12):1107-13. doi: 10.1001/archsurg.2012.1962.</citation>
    <PMID>22910846</PMID>
  </results_reference>
  <results_reference>
    <citation>Doussot A, Lim C, GÃ³mez-Gavara C, Fuks D, Farges O, Regimbeau JM, Azoulay D; AFC-IHCC Study Group. Multicentre study of the impact of morbidity on long-term survival following hepatectomy for intrahepatic cholangiocarcinoma. Br J Surg. 2016 Dec;103(13):1887-1894. doi: 10.1002/bjs.10296. Epub 2016 Sep 15. Erratum in: Br J Surg. 2017 Dec;104(13):1895.</citation>
    <PMID>27629502</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>May 10, 2020</last_update_submitted>
  <last_update_submitted_qc>May 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

